26
total announcements
ANTHEM.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 15 Oct 2026
Market Cap
₹47,619 Cr
P/E (TTM)
85.7
P/E (Forward)
56.1
EPS (TTM)
₹9.89
52W Low
₹579.15
52W High
₹977.55
Dividend Yield
0.23%
Price / Book
15.7
Debt / Equity
1.8
Revenue (TTM)
₹2,007 Cr
Gross Margin
61.66%
Operating Margin
28.83%
Anthem Biosciences Limited
Anthem Biosciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
Anthem Biosciences Limited
Anthem Biosciences Limited has informed the Exchange regarding the settlement of its upside sharing arrangement, which was approved by public shareholders at the Annual General Meeting held on July 22, 2026.
Anthem Biosciences Limited
Anthem Biosciences Limited has announced its Q1 FY27 results, with consolidated revenues from operations at Rs. 418 crores, EBITDA at Rs. 176 crores, and PAT at Rs. 120 crores. The company's net cash position as of June 30, 2026, was Rs. 1,720 crores. The management has stated that the underlying demand remains strong, with a higher concentration of scheduled deliveries in the latter half of the year.
Anthem Biosciences Limited
Anthem Biosciences Limited has announced the voting results and Srutinizers report of the 20th Annual General Meeting held on July 22, 2026.
Anthem Biosciences Limited
Anthem Biosciences Limited held its 20th Annual General Meeting on July 22, 2026, through video conferencing, where the company's financial statements for FY 2025-26 were approved, and various resolutions were passed, including the appointment of new auditors and the continuation of a non-executive director.
Anthem Biosciences Limited
Anthem Biosciences Limited has informed the Exchange about the link of the recording of their Earnings Call for the quarter ended June 30, 2026, which is available on their website.
Anthem Biosciences Limited
Anthem Biosciences Limited has published the unaudited consolidated and standalone financial results for the quarter ended June 30, 2026, in accordance with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Anthem Biosciences Limited
Anthem Biosciences Limited has revised its press release for Q1FY27 unaudited consolidated financial results, with consolidated revenue from operations at ₹4,182 Mn, EBITDA at ₹1,755 Mn, and PAT at ₹1,199 Mn.
Anthem Biosciences Limited
Anthem Biosciences Limited has informed the Exchange about Investor Presentation, which includes revised Earnings Call Presentation for Q1FY27. The company has reported ₹4,182 Mn revenue from operations, ₹1,755 Mn EBITDA, and ₹1,199 Mn PAT. The net cash position as of June 30, 2026, is ₹17,197 Mn.
Anthem Biosciences Limited
Anthem Biosciences Limited has announced its unaudited consolidated financial results for the quarter ended June 30, 2026, with revenue from operations at ₹4,182 Mn, EBITDA at ₹1,755 Mn, and PAT at ₹1,199 Mn.
Anthem Biosciences Limited
Anthem Biosciences Limited has announced its Q1FY27 consolidated financial results, with revenue from operations at ₹4,182 Mn, EBITDA at ₹1,755 Mn, and PAT at ₹1,199 Mn. The company's net cash position as of June 30, 2026, is ₹17,197 Mn.
Anthem Biosciences Limited
Anthem Biosciences Limited has submitted its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, which were reviewed by the Board of Directors and approved by the Audit Committee.
Anthem Biosciences Limited
Anthem Biosciences Limited has scheduled an earnings conference call to discuss its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.
Anthem Biosciences Limited
Anthem Biosciences Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the details of securities dematerialized or rematerialized during the quarter ended June 30, 2026.
Anthem Biosciences Limited
Anthem Biosciences Limited has submitted a disclosure under SEBI Takeover Regulations, indicating a potential takeover or acquisition activity.
Anthem Biosciences Limited
Anthem Biosciences Limited has informed the Exchange regarding the Letter to Shareholders providing the weblink and navigation path for accessing the Annual Report for the FY 2025-26 pursuant to Regulation 36(1)(b) of LODR.
Anthem Biosciences Limited
Anthem Biosciences Limited has informed the Exchange about a revision in credit rating by ICRA Limited, upgrading the ratings to AA (Stable) for various bank facilities, with outlook revised to Stable from Positive.
Anthem Biosciences Limited
Anthem Biosciences Limited clarifies discrepancies in its financial results for the quarter and year ended March 31, 2026, including a mismatch in yearly PAT figures and non-disclosure of consolidated EPS in XBRL filing.
Anthem Biosciences Limited
Anthem Biosciences Limited has informed the Exchange about the newspaper advertisement regarding the completion of dispatch of notice of the 20th Annual General Meeting of the Company.
Anthem Biosciences Limited
Anthem Biosciences Limited has voluntarily published its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26, ahead of the mandatory requirement from FY 2026-27.